Additionally, humanized anti-CD6 mAb (Itolizumab) effectively treats psoriasis and rheumatoid arthritis by strongly suppressing pro-inflammatory cytokine production and Th1/17 cell proliferation [70,71]. Here, CD6 is linked to psoriasis.